scholarly journals FLASH Radiotherapy: a Promising Direction in the Fight Against Cancer

2021 ◽  
Vol 102 (4) ◽  
pp. 240-246
Author(s):  
А. V. Каrtashev ◽  
Т. N. Bochkareva ◽  
А. S. Anokhina
Keyword(s):  
Local Control ◽  
Ultrashort Pulse ◽  
Clinical Studies ◽  
Technological Progress ◽  
High Dose ◽  
Present Stage ◽  
Promising Direction ◽  
Normal Tissues ◽  
Experimental Findings ◽  
Fight Against Cancer

At the present stage of scientific and technological progress, high-dose radiotherapy has become a common way to combat severe cancers. However, this treatment option is limited by normal tissues radiosensitivity. The developed technology of ultrashort pulse delivery of a dose of ionizing radiation to the zone of interest (FLASH radiotherapy) can achieve a high local control over tumor growth while sparing healthy tissues. This review summarizes the experimental findings supporting the possibility of transitioning to clinical studies of FLASH radiotherapy.

Resveratrol as an Adjuvant for Normal Tissues Protection and Tumor Sensitization

2020 ◽  
Vol 20 (2) ◽  
pp. 130-145 ◽  
Author(s):  
Keywan Mortezaee ◽  
Masoud Najafi ◽  
Bagher Farhood ◽  
Amirhossein Ahmadi ◽  
Dheyauldeen Shabeeb ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Cancer Treatment ◽  
Cancer Cells ◽  
Clinical Studies ◽  
Normal Tissue ◽  
Medical Science ◽  
Treatment Modalities ◽  
Radiation Toxicity ◽  
Normal Tissues ◽  
Normal Tissue Toxicity

Cancer is one of the most complicated diseases in present-day medical science. Yearly, several studies suggest various strategies for preventing carcinogenesis. Furthermore, experiments for the treatment of cancer with low side effects are ongoing. Chemotherapy, targeted therapy, radiotherapy and immunotherapy are the most common non-invasive strategies for cancer treatment. One of the most challenging issues encountered with these modalities is low effectiveness, as well as normal tissue toxicity for chemo-radiation therapy. The use of some agents as adjuvants has been suggested to improve tumor responses and also alleviate normal tissue toxicity. Resveratrol, a natural flavonoid, has attracted a lot of attention for the management of both tumor and normal tissue responses to various modalities of cancer therapy. As an antioxidant and anti-inflammatory agent, in vitro and in vivo studies show that it is able to mitigate chemo-radiation toxicity in normal tissues. However, clinical studies to confirm the usage of resveratrol as a chemo-radioprotector are lacking. In addition, it can sensitize various types of cancer cells to both chemotherapy drugs and radiation. In recent years, some clinical studies suggested that resveratrol may have an effect on inducing cancer cell killing. Yet, clinical translation of resveratrol has not yielded desirable results for the combination of resveratrol with radiotherapy, targeted therapy or immunotherapy. In this paper, we review the potential role of resveratrol for preserving normal tissues and sensitization of cancer cells in combination with different cancer treatment modalities.

On the clinical significance of HDL cholesterol at the present stage

2021 ◽  
Vol 19 (1) ◽  
pp. 50-53
Author(s):  
V. N. Oslopov ◽  
◽  
Yu. V. Oslopova ◽  
E. V. Khazova ◽  
E. R. Girfanutdinova ◽  
...  
Keyword(s):  
Cardiovascular Diseases ◽  
Blood Plasma ◽  
Clinical Studies ◽  
Hdl Cholesterol ◽  
Epidemiological Studies ◽  
Present Stage ◽  
The World ◽  
Cast Doubt ◽  
And Function ◽  
Role And Function

The leading death cause in the world is diseases of the cardiovascular system, with CHD as the leader in the structure of cardiovascular diseases. The cause of this disease is atherosclerosis. One of the possible causes of atherosclerosis is an increase in LDL-C and a decrease in HDL-C in the blood. Many epidemiological studies have reliably shown that HDL cholesterol reduces the risk of developing cardiovascular diseases. Data from recent studies cast doubt on this data. The review briefly describes the current understanding of the effect of HDL-C high levels on morbidity and mortality, lists the new approaches to assessing the role and function of these particles, presents the results of clinical studies of drugs that affect their concentration in blood plasma and the probable causes leading to an increase of the HDL-Cin content in the blood.

scholarly journals Stereotactic Ablative Radiotherapy for the Treatment of Oligometastatic Cancer: A Clinical Review as Part of a Health Technology Assessment

2021 ◽  
Vol 1 (3) ◽  
Author(s):  
Chantelle C. Lachance ◽  
Khai Tran ◽  
Elizabeth Carson ◽  
Joanne Kim ◽  
David Palma ◽  
...  
Keyword(s):  
Clinical Review ◽  
Treatment Options ◽  
Progression Free Survival ◽  
Clinical Effectiveness ◽  
Standard Of Care ◽  
The Body ◽  
Stereotactic Ablative Radiotherapy ◽  
High Dose ◽  
Normal Tissues ◽  
Oligometastatic Cancer

Oligometastatic cancer (cancer with a limited number of metastases) represents an intermediate state between cancer confined to a single location in the body and cancer that has metastasized — or spread — widely. One treatment option, for which there is growing interest, is stereotactic ablative radiotherapy, also known as SABR. SABR precisely delivers a high dose of radiation to ablate tumours at specific sites while minimizing the radiation dose to surrounding normal tissues. SABR may be used independently or alongside other treatment options in the management of oligometastatic cancer. This CADTH clinical review evaluated the evidence regarding the clinical effectiveness and safety of SABR with or without standard of care (SOC) for people with oligometastatic cancer and found the following: SABR in addition to SOC may offer a benefit in terms of overall survival (OS) and progression-free survival (PFS). The findings for the effectiveness of SABR alone compared with SOC were mixed and deemed inconclusive. There are insufficient data related to adverse events (AEs) at the present time to draw conclusions regarding the safety of SABR relative to SOC alternatives. Note that the CADTH Clinical Review Report will be updated every 3 months to ensure the findings remain up-to-date as new evidence emerges.

High dose therapy (autologus transplant)

2007 ◽  
pp. 261-268
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Suppression ◽  
Limiting Factor ◽  
High Dose ◽  
Cure Rate ◽  
High Dose Therapy ◽  
Dose Therapy ◽  
Normal Tissues ◽  
Higher Doses

Principles and uses 262 Conditioning 264 Nursing issues of high dose therapy 266 Many haematological cancers are treated more effectively by higher doses of chemotherapy and radiotherapy than by lower doses. Continuing to escalate the dose given will theoretically increase the cure rate. However, the dose-limiting factor is the toxicity to normal tissues. The first tissue to be seriously affected is the bone marrow. Bone marrow suppression results in:...

Role of prostaglandins in contractile activity of the ampulla of the rabbit oviduct

1980 ◽  
Vol 238 (2) ◽  
pp. E157-E166 ◽  
Author(s):  
M. J. Harper ◽  
L. W. Coons ◽  
D. A. Radicke ◽  
B. J. Hodgson ◽  
G. Valenzuela
Keyword(s):  
Spontaneous Activity ◽  
Contractile Activity ◽  
Prostaglandin E ◽  
High Dose ◽  
Field Stimulation ◽  
Prostaglandin Synthetase ◽  
Response Curves ◽  
Normal Tissues

Contractile activity of the ampulla of rabbit oviducts removed 24 h after an ovulating injection was studied in vitro. Spontaneous activity, field-stimulated activity, and response to phenylephrine were studied in normal, reversed, and scraped (endosalpinx removed) sections of tissues in the presence or absence of inhibitors of prostaglandin synthetase (8 or 51 micrograms/ml indomethacin or 10 or 100 micrograms/ml 5,8,11,14-eicosatetraynoic acid (ETA)). The effects of in vivo treatment with 10 mg/kg of indomethacin on the same responses were examined. Scraped tissues produced more prostaglandin E and F (measured by radioimmunoassay) than did normal tissues, and this production was suppressed by 10 micrograms/ml of indomethacin or 100 micrograms/ml of ETA. Production of prostaglandin by normal tissues was not depressed by these compounds in vitro, but was significantly reduced by pretreatment of the animals with indomethacin in vivo. In the absence of the endosalpinx, the myosalpinx exhibited spontaneous activity and responded to field stimulation and phenylephrine. Scraped and reversed tissues, however, showed a faster decline in response to field stimulation than normal tissues, and this was due to the traumatization. By contrast, traumatization increased the sensitivity of the tissue to respond to phenylephrine. Inhibition of prostaglandin synthetase by low doses of indomethacin or ETA prevented desensitization of the tissue to field stimulation, but this desensitization was little affected by the higher doses of indomethacin in vitro or in vivo. ETA did not affect the phenylephrine dose-response curves and nor did 8 micrograms/ml of indomethacin, whereas the high dose was inhibitory. Spontaneous activity was only affected by the in vivo pretreatment with indomethacin, which prevented the decline in activity of scraped tissue with time.

Cessation and reduction in alcohol consumption and misuse after psychedelic use

2019 ◽  
Vol 33 (9) ◽  
pp. 1088-1101 ◽  
Author(s):  
Albert Garcia-Romeu ◽  
Alan K Davis ◽  
Fire Erowid ◽  
Earth Erowid ◽  
Roland R Griffiths ◽  
...  
Keyword(s):  
Alcohol Consumption ◽  
Alcohol Use ◽  
Clinical Studies ◽  
Online Survey ◽  
Meta Analysis ◽  
High Dose ◽  
Clinical Settings ◽  
Problematic Alcohol ◽  
The Usa ◽  
Problematic Alcohol Use

Background:Meta-analysis of randomized studies using lysergic acid diethylamide (LSD) for alcohol use disorder (AUD) showed large, significant effects for LSD efficacy compared to control conditions. Clinical studies suggest potential anti-addiction effects of LSD and mechanistically-related classic psychedelics for alcohol and other substance use disorders.Aims:To supplement clinical studies, reports of psychedelic use in naturalistic settings can provide further data regarding potential effects of psychedelics on alcohol use.Methods:An anonymous online survey of individuals with prior AUD reporting cessation or reduction in alcohol use following psychedelic use in non-clinical settings.Results:343 respondents, mostly White (89%), males (78%), in the USA (60%) completed the survey. Participants reported seven years of problematic alcohol use on average before the psychedelic experience to which they attributed reduced alcohol consumption, with 72% meeting retrospective criteria for severe AUD. Most reported taking a moderate or high dose of LSD (38%) or psilocybin (36%), followed by significant reduction in alcohol consumption. After the psychedelic experience 83% no longer met AUD criteria. Participants rated their psychedelic experience as highly meaningful and insightful, with 28% endorsing psychedelic-associated changes in life priorities or values as facilitating reduced alcohol misuse. Greater psychedelic dose, insight, mystical-type effects, and personal meaning of experiences were associated with a greater reduction in alcohol consumption, controlling for prior alcohol consumption and related distress.Conclusions:Although results cannot demonstrate causality, they suggest that naturalistic psychedelic use may lead to cessation or reduction in problematic alcohol use, supporting further investigation of psychedelic-assisted treatment for AUD.

Sign in / Sign up

Export Citation Format

Share Document